<DOC>
	<DOCNO>NCT02015715</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , single ascend dose study assess safety , pharmacokinetics , pharmacodynamics RO6864018 healthy , male , Asian Caucasian participant . Participants enrol cohort randomize 8:2 receive single oral administration RO6864018 placebo . Total study duration participant 9 week .</brief_summary>
	<brief_title>A Study Evaluating Safety , Pharmacokinetics , Pharmacodynamics RO6864018 Male , Healthy , Asian Participants</brief_title>
	<detailed_description />
	<criteria>Healthy male participant ethnic Chinese , Korean , Japanese origin Caucasian No sign active chronic disease follow detailed medical surgical history , complete physical examination include vital sign , 12lead electrocardiogram ( ECG ) , hematology , blood chemistry , serology urinalysis Body Mass Index ( BMI ) 18 30 kilogram per square meter ( kg/m^2 ) inclusive , weight range 50 100 kilogram ( kg ) ( 110 220 pound [ lb ] ) inclusive screen Nonsmokers , use le ( &lt; ) 10 cigarette ( equivalent nicotinecontaining product ) per day History symptom significant disease Personal family history congenital long QT syndrome sudden death Any confirm significant allergic reaction drug , multiple drug allergy ( nonactive hay fever acceptable ) Positive result antinuclear antibody ( ANA ) , antimitochondrial antibody ( AMA ) , antismooth muscle antibody ( ASMA ) thyroid peroxidase antibody Suspicion regular consumption drug abuse History ( within 3 month screen ) alcohol consumption exceed 14 unit per week average ( 1 unit = 10 gram alcohol ) Participants receive Interferon ( IFN ) peginterferon within 8 week prior dose Use medication ( prescription counter [ OTC ] , include health supplement herbal remedy ) within 2 week first dose study medication Positive Hepatitis A immunoglobulin M antibody ( HAV IgM Ab ) , Hepatitis B surface antigen ( HBsAg ) , Hepatitis C antibody ( HCV Ab ) human immunodeficiency virus antibody ( HIV Ab ) screen Donation loss blood great 500 milliliter ( mL ) within 90 day prior dose Have participate clinical study within 60 day prior study randomization</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>